Lupin joins hands with Alvion to commercialize Cardiometabolic medicines in Southeast Asia
Mumbai: Global pharma major, Lupin Limited, announced today that the company has entered into a licensing agreement with Alvion Pharmaceuticals P.C. to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.
Commenting on the announcement, Gabriel Georgy, Regional Head Southeast Asia, Lupin said "Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost effective alternatives for patients and the healthcare system. Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region. We look forward to expanding our partnership with Alvion over the coming years."
By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin will play a significant role in improving the quality of healthcare and access to medicines.
Read also: Lupin bags USFDA nod for Sildenafil for Oral Suspension
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.